Pomerantz Law Firm Investigates LENZ Therapeutics for Potential Securities Fraud Claims
News provided byLENZ Therapeutics, Inc · 1 min read
NEW YORK, Sept. 3, 2026 /CourierPR/ -- Pomerantz Law Firm is investigating potential securities fraud claims on behalf of investors of LENZ Therapeutics, Inc. (NASDAQ: LENZ), according to a recent press release.
On August 11, 2026, LENZ reported its second quarter 2026 financial results. While the company reported a total revenue of $5.5 million, a significant portion of this amount, $3.8 million, was attributed to one-time, non-product global licensing milestones. Organic product sales for the company's primary commercial eye drop, VIZZ, amounted to $1.73 million, representing only a 9% increase in volume compared to the previous quarter. This modest growth in organic sales, coupled with the heavy reliance on one-time milestones, raised concerns among investors.
The next day, August 12, 2026, Bank of America downgraded LENZ stock from "Buy" to "Neutral" and reduced its price target from $31.00 to $7.00, citing a slower-than-expected commercial launch for VIZZ. This downgrade prompted a significant drop in LENZ's stock price, causing substantial financial damage to its investors.
Pomerantz LLP, based in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is a leading firm in corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, the firm has been at the forefront of securities class actions for over 85 years. Pomerantz has secured numerous multimillion-dollar damage awards on behalf of class members and continues to advocate for the rights of victims of securities fraud and corporate misconduct.